Farmakokinetika — разлика између измена
Садржај обрисан Садржај додат
м Разне исправке |
м →Literatura: претварање PMID веза у шаблон |
||
Ред 26:
* Beal, S.; Sheiner L.B. "The NONMEM System". The American Statistician 34: 118–9. (1980). {{doi|10.2307/2684123}}.
* Cooper, ''La célula'', pág 470-471, 2ª edición, Ed. Marbán
* Covey TR, Lee ED, Henion JD "High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples". Anal. Chem. 58: 2453–60. (October 1986). {{doi|10.1021/ac00125a022}}. {{PMID
* Covey TR, JB Crowther, EA Dewey, JD Henion "Thermospray liquid chromatography/mass spectrometry determination of drugs and their metabolites in biological fluids". Anal. Chem. 57 (2): 474–81. (February 1985). {{doi|10.1021/ac50001a036}}. {{PMID
* Danielson P (2002). "The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans". Curr Drug Metab 3 (6): 561-97. {{PMID
* Davies K (1995). "Oxidative stress: the paradox of aerobic life". Biochem Soc Symp 61: 1-31. {{PMID
* Devlin, T. M. 2004. ''Bioquímica'', 4ª edición. Reverté, Barcelona. {{page|year=|isbn=978-84-291-7208-9|pages=}}
* Galvão T, Mohn W, de Lorenzo V (2005). "Exploring the microbial biodegradation and biotransformation gene pool". Trends Biotechnol 23 (10): 497-506. {{PMID
* Hsieh Y, Korfmacher WA "Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening". Current Drug Metabolism 7 (5): 479–89.(June 2006). {{PMID
* Janssen D, Dinkla I, Poelarends G, Terpstra P (2005). "Bacterial degradation of xenobiotic compounds: evolution and distribution of novel enzyme activities". Environ Microbiol 7 (12): 1868-82. {{PMID
* Kathleen Knights; Bronwen Bryant (2002). ''Pharmacology for Health Professionals''. Amsterdam: Elsevier. {{page|year=|isbn=978-0-7295-3664-6|pages=}}.
* King C, Rios G, Green M, Tephly T (2000). "UDP-glucuronosyltransferases". Curr Drug Metab 1 (2): 143-61. {{PMID
* Malcolm Rowland, Thomas N. Tozer. "Farmacocinética clínica: Conceptos y Aplicaciones"
* Pharmacokinetics. (2006). En ''Mosby's Dictionary of Medicine, Nursing, & Health Professions''. Philadelphia, PA: Elsevier Health Sciences. Disponible en [http://www.credoreference.com/entry/6686418] Última visita 11, diciembre de 2008,
* Sheehan D, Meade G, Foley V, Dowd C (2001). "Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily". Biochem J 360 (Pt 1): 1-16. {{PMID
* Sheiner, L.B.; Beal, S.L., Rosenberg, B. Marathe, V.V. "Forecasting Individual Pharmacokinetics". Clin. Pharmacol. Ther. 26: 294–305. (1979). {{PMID
* Sheiner, L.B.; Rosenberg, B., Marathe, V.V. "Estimation of Population Characteristics of Pharmacokinetic Parameters from Routine Clinical Data". J. Pharmacokin. Biopharm. 5: 445–79. 1.997 {{doi|10.1007/BF01061728}}.
* Sies H (1997). "Oxidative stress: oxidants and antioxidants". Exp Physiol 82 (2): 291-5. {{PMID
* Singh SS., ''Preclinical pharmacokinetics: an approach towards safer and efficacious drugs'', Curr Drug Metab. 2006 Feb;7(2):165-82.
* Testa B, Krämer S (2006). "The biochemistry of drug metabolism--an introduction: part 1. Principles and overview". Chem Biodivers 3 (10): 1053-101. {{PMID
* Tetko IV, Bruneau P, Mewes HW, Rohrer DC, Poda GI., ''Can we estimate the accuracy of ADME-Tox predictions?,'' [http://dx.doi.org/10.1016/j.drudis.2006.06.013 Drug Discov Today]. 2006 Aug;11(15—16):700-7, [http://www.vcclab.org/~itetko/DDT.pdf pre-print].
* Tu B, Weissman J (2004). "Oxidative protein folding in eukaryotes: mechanisms and consequences". J Cell Biol 164 (3): 341-6. {{PMID
* Vertuani S, Angusti A, Manfredini S (2004). "The antioxidants and pro-antioxidants network: an overview". Curr Pharm Des 10 (14): 1677-94. {{PMID
{{refend}}
| |||